Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 49 citing articles:

GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives
Riccardo Nevola, Raffaella Epifani, Simona Imbriani, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 2, pp. 1703-1703
Open Access | Times Cited: 133
The non-steroidal mineralocorticoid receptor antagonist finerenone and heart failure with preserved ejection fraction
Ulrich Kintscher, Frank Edelmann
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 25
GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes: Pleiotropic Cardiometabolic Effects and Add-on Value of a Combined Therapy
André Scheen
Drugs (2024)
Closed Access | Times Cited: 7
MASLD and MASH at the crossroads of hepatology trials and cardiorenal metabolic trials
Faı̈ez Zannad, Arun J. Sanyal, Javed Butler, et al.
Journal of Internal Medicine (2024) Vol. 296, Iss. 1, pp. 24-38
Open Access | Times Cited: 6
Comparative renal outcomes of matched cohorts of patients with type 2 diabetes receiving SGLT2 inhibitors or GLP-1 receptor agonists under routine care
Gian Paolo Fadini, Enrico Longato, Mario Luca Morieri, et al.
Diabetologia (2024) Vol. 67, Iss. 11, pp. 2585-2597
Open Access | Times Cited: 6
Comparative efficacy of sodium‐glucose co‐transporter‐2 inhibitors, glucagon‐like peptide‐1 receptor agonists and non‐steroidal mineralocorticoid receptor antagonists in chronic kidney disease and type 2 diabetes: A systematic review and network meta‐analysis
Bao N. Nguyen, Le Kim Chi Nguyen, Shweta Mital, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 6, pp. 1614-1623
Closed Access | Times Cited: 12
Finerenone attenuates myocardial apoptosis, metabolic disturbance and myocardial fibrosis in type 2 diabetes mellitus
Tao Jin, Xiangrui Fu, Ming Liu, et al.
Diabetology & Metabolic Syndrome (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 11
Effects of finerenone and glucagon-like peptide 1 receptor agonists on cardiovascular and renal outcomes in type 2 diabetes mellitus: a systematic review and meta-analysis
Xia Gu, Shimin Jiang, Yue Yang, et al.
Diabetology & Metabolic Syndrome (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 4
Sodium-Glucose Co-Transporter 2 Inhibitors: Mechanism of Action and Efficacy in Non-Diabetic Kidney Disease from Bench to Bed-Side
Aly M. Abdelrahman, Alaa S. Awad, Emaad M. Abdel‐Rahman
Journal of Clinical Medicine (2024) Vol. 13, Iss. 4, pp. 956-956
Open Access | Times Cited: 4
Effect of Finerenone in Cardiovascular and Renal Outcomes: A Systematic Review and Meta-analysis
Juan Carlos Rivera-Martinez, Michael Sabina, Aqeel Khanani, et al.
Cardiovascular Drugs and Therapy (2025)
Open Access
Análise das diferentes respostas ao tratamento com agonistas GLP-1 em diabetes tipo 1 e tipo 2 e a personalização dos tratamentos
G. F. de Carvalho, GUSTAVO PACIFICO MAIA ANTERO DE SOUSA, Gabriel Moraes, et al.
Contribuciones a las Ciencias Sociales (2025) Vol. 18, Iss. 1, pp. e14682-e14682
Closed Access
Multidisciplinary care model for nutrition and glycemic control in CKD and diabetes
Suge Tian, Jing Zhang, Fengjie Zhang, et al.
Asian Journal of Surgery (2025)
Open Access
Cardiovascular Safety Profile of Semaglutide and Variations by Sex, Race, and Kidney Function: A Systematic Review and Meta-analysis
Muhammad Hamayal, Chaudhary Humayun Akhtar, Naveed Ahmad, et al.
American Journal of Cardiovascular Drugs (2025)
Closed Access
Role and application prospective of non-steroidal MRA in the treatment of diabetic kidney disease
Yuying Sun, Mingzhu Wang
International Urology and Nephrology (2025)
Closed Access
Clinical efficacy and safety of sodium-glucose cotransporter protein-2 (SGLT-2) inhibitor, glucagon-like peptide-1 (GLP-1) receptor agonist, and Finerenone in type 2 diabetes mellitus with non-dialysis chronic kidney disease: a network meta-analysis of randomized clinical trials
Jingyi Guo, Maoying Wei, Wen‐Hua Zhang, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Clinical Guidelines of the Russian Society for the Study of the Liver, Russian Gastroenterological Association, Russian Society for the Prevention of Non-Communicable Diseases, Russian Association of Endocrinologists, Russian Scientific Medical Society of Therapists, National Society of Preventive Cardiology, Russian Association of Gerontologists and Geriatricians on Non-Alcoholic Fatty Liver Disease
В. Т. Ивашкин, О. М. Драпкина, M. V. Maevskaya, et al.
Russian Journal of Gastroenterology Hepatology Coloproctology (2025) Vol. 35, Iss. 1, pp. 94-152
Open Access
Comparative Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists and Sodium/Glucose Cotransporter 2 Inhibitors in Preventing Chronic Kidney Failure and Mortality in Patients With Type 2 Diabetes and CKD
Yen‐Chieh Lee, Li-Chiu Wu, Vin‐Cent Wu, et al.
American Journal of Kidney Diseases (2025)
Closed Access
Comparative efficacy and safety of SGLT2is and ns-MRAs in patients with diabetic kidney disease: a systematic review and network meta-analysis
Siqi Yang, Xi Zhao, Jing Zhang, et al.
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 3
Comparison of GLP‐1 Receptor Agonists, SGLT‐2 Inhibitors, and DPP‐4 Inhibitors as an Add‐On Drug to Insulin Combined With Oral Hypoglycemic Drugs: Umbrella Review
Sanbao Chai, Yapin Niu, Fengqi Liu, et al.
Journal of Diabetes Research (2024) Vol. 2024, Iss. 1
Open Access | Times Cited: 3
Integrating liver endpoints in clinical trials of cardiovascular and kidney disease
Faı̈ez Zannad, Arun J. Sanyal, Javed Butler, et al.
Nature Medicine (2024) Vol. 30, Iss. 9, pp. 2423-2431
Closed Access | Times Cited: 3
Therapie des Typ-2-Diabetes
Baptist Gallwitz, Jens Aberle, Andreas L. Birkenfeld, et al.
Diabetologie und Stoffwechsel (2024) Vol. 19, Iss. S 02, pp. S186-S202
Closed Access | Times Cited: 3
Is Tirzepatide the New Game Changer in Type 2 Diabetes?
Giuseppe Lisco, Olga Disoteo, Vincenzo De Geronimo, et al.
Endocrines (2024) Vol. 5, Iss. 1, pp. 72-86
Open Access | Times Cited: 2
The significance of finerenone as a novel therapeutic option in diabetic kidney disease: a scoping review with emphasis on cardiorenal outcomes of the finerenone phase 3 trials
Mustafa Kemal Arıcı, Bulent Altun, Mustafa Araz, et al.
Frontiers in Medicine (2024) Vol. 11
Open Access | Times Cited: 2
Impact of DPP-4 Inhibitors in Patients with Diabetes Mellitus and Heart Failure: An In-Depth Review
Francisco Epelde
Medicina (2024) Vol. 60, Iss. 12, pp. 1986-1986
Open Access | Times Cited: 2
Novel pharmacological interventions for diabetic kidney disease
Seng Kiong Tan, Jairo A Pinzón-Cortés, Mark E. Cooper
Current Opinion in Nephrology & Hypertension (2023) Vol. 33, Iss. 1, pp. 13-25
Closed Access | Times Cited: 5
Page 1 - Next Page

Scroll to top